Markets

bioAffinity Technologies Announces 100% Increase In Sales For Its CyPath Lung Test For Lung Cancer

Oct 6, 2026 · 09:23 AM ET· updated 13h ago

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that sales of its CyPath®

Why It Matters

bioAffinity's lung cancer test doubled in sales this period. When a company's product sells twice as much, it shows doctors and patients are trusting it more.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BIAF6.00

-0.19 (-3.07%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.